Get the Stockscreener App
10.32
0.49%
0.05
After Hours:
10.33
0.010
+0.10%
Stoke Therapeutics Inc Stock (STOK) Latest News
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7%Here's Why - MarketBeat
Long Term Trading Analysis for (STOK) - Stock Traders Daily
Understanding the 7.51% Volatility Levels of Stoke Therapeutics Inc’s (STOK) Stock in the Past 30 Days - The News Heater
STOK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 8.2%Here's Why - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Average Price Target from Analysts - Armenian Reporter
Stoke Therapeutics Inc (STOK) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Stoke Therapeutics Inc: Rising -28.33% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Trading Day Review: Stoke Therapeutics Inc (STOK) Gains Momentum, Closing at 12.60 - The Dwinnex
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength? - Yahoo Finance
FY2025 Earnings Estimate for STOK Issued By Leerink Partnrs - MarketBeat
STOK (Stoke Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Are Stoke Therapeutics Inc (STOK) shares a good deal now? - US Post News
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Morgan Stanley Reduces Stake in Stoke Therapeutics Inc - GuruFocus.com
Stoke Therapeutics (NASDAQ:STOK) Shares Up 6.9%Should You Buy? - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Trading Down 5.6%Here's What Happened - MarketBeat
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
How to Take Advantage of moves in (STOK) - Stock Traders Daily
The 13% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 116% - Yahoo Finance
Stoke Therapeutics (NASDAQ:STOK) Trading Up 6.3%Here's What Happened - MarketBeat
Cantor Fitzgerald Forecasts STOK FY2025 Earnings - Defense World
Brokers Offer Predictions for STOK FY2025 Earnings - MarketBeat
Possible Signal As Stoke Therapeutics Insiders Sell US$523k In Stock - Simply Wall St
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? - MSN
When the Price of (STOK) Talks, People Listen - Stock Traders Daily
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 9.7%Time to Buy? - MarketBeat
Barclays PLC Raises Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Is Stoke Therapeutics Inc (NASDAQ: STOK) Still Trending? - Stocks Register
Head-To-Head Contrast: Inhibitor Therapeutics (OTCMKTS:INTI) and Stoke Therapeutics (NASDAQ:STOK) - Defense World
Q1 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World
Stoke Therapeutics Inc (STOK): Worth A Small Bite At $8.92 - Stocks Register
Wedbush Equities Analysts Raise Earnings Estimates for STOK - MarketBeat
What is Wedbush’s Estimate for STOK FY2029 Earnings? - Defense World
Research Analysts Offer Predictions for STOK FY2029 Earnings - MarketBeat
Learn to Evaluate (STOK) using the Charts - Stock Traders Daily
Stoke Therapeutics to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Analyst maintains OW rating on Stoke Therapeutics as P3 EMPEROR study design finalized - Investing.com Canada
Needham & Company LLC Reiterates "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK) - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Receives "Buy" Rating from HC Wainwright - MarketBeat
The Analyst Verdict: Stoke Therapeutics In The Eyes Of 4 Experts - Benzinga
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):